RT Book, Section
A1 Burnett, Arthur L.
A2 Feneley, Mark R.
A2 Payne, Heather A.
SR Print(0)
ID 1152371621
T1 Treatment strategies for erectile dysfunction
T2 Therapeutic Strategies in Prostate Cancer
YR 2018
FD 2018
PB Clinical Publishing
PP New York, NY
SN 9781904392880
LK hemonc.mhmedical.com/content.aspx?aid=1152371621
RD 2021/01/27
AB In  recent  years,  prostate  cancer  has  emerged  from  an  often  trivialized  medical  condition,  relegated  to  older  men  and  thought  to  exert  little  lifetime  consequence,  to  a  disease  state  of  major  importance.  The  significance  of  the  disease  has  increased  in  large  part  because  of  its  dramatic  stage  migration  in  the  modern  prostate-specific  antigen  (PSA)  era,  and  this  is  typified  by  increasingly  early  clinical  stage  diagnoses  and  diagnoses  made  increasingly  in  young  men.  As  a  result,  the  need  exists  for  improved  disease  control  via  effective  oncological  control  while  maximally  preserving  functional  outcomes.  This  matter  is  most  noteworthy  in  the  area  of  erectile  function,  particularly  as  it  is  viewed  that  other  historical  complications  of  treatment,  such  as  urinary  incontinence  following  radical  prostatectomy,  have  greatly  been  reduced  [1].  Indeed,  as  patients  currently  consider  the  impact  of  various  treatment  approaches  for  prostate  cancer  on  their  quality  of  life,  many  place  paramount  importance  on  the  opportunity  for  retaining  natural  erectile  function  [2].